Clinical trials: Neuropsychiatric Syndrome
HIV Infections
The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215
The lack of success in treating substance abuse may be contributed to by a limited understanding of the clinical neurobiology of drug abuse.
- Trial name
- NCT01034800
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Obsessive-compulsive Disorder With Acute Onset, PANDAS
PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort
Background: Obsessive-compulsive disorder (OCD) is considered one of the most debilitating of the psychiatric illnesses, yet much remains unclear regarding causes and cures.
- Conditions
- Obsessive-compulsive Disorder With Acute Onset, PANDAS, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
- Trial name
- NCT02190292
- Where
- Sweden
- Volunteers
- 185 people
- Sponsor
- Karolinska Institutet
Neuropsychiatric Syndrome, Autism Spectrum Disorder
Nature and Animal-assisted Activities
Neuropsychiatric impairments in young adults are common and can involve social withdrawal, and difficulties in receiving support from healthcare and municipal social care services.
- Trial name
- NCT06431126
- Testing
- Nature and animal-assisted activities
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Kronoberg County Council
Mental Disorder
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
Use of the drug interferon-alpha (IFN-A), is associated with frequent and well characterized side effects like neurotoxicity. Neurotoxicity can cause symptoms of depression, agitation, anxiety, and/or confusion.
- Trial name
- NCT00001547
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Mental Health (NIMH)
Psychiatric or Mood Diseases or Conditions, Neuropsychiatric Syndrome
Effect and Cost-effectiveness of the Everyday Life Rehabilitation Intervention
The person-centered, motivational, recovery-, and activity-based intervention model 'Everyday Life Rehabilitation´ (ELR), integrated in sheltered and supported housing facilities for people with severe psychiatric disabilities…
- Conditions
- Psychiatric or Mood Diseases or Conditions, Neuropsychiatric Syndrome, Psychosis, Autism
- Trial name
- ELR (NCT05056415)
- Testing
- Everyday Life Rehabilitation (ELR), Treatment as usual (TAU)
- Where
- Sweden
- Volunteers
- 161 people
- Sponsor
- Umeå University
PANS, PANDAS
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
This study is a brief (3 month) longitudinal study following children between the ages of 4-16 years old who have been diagnosed with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
- Trial name
- NCT04382716
- Testing
- No intervention
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
HIV Infections, Cognition Disorders
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).
To study the safety, toxicology, and activity of Peptide T (D-Ala-1-peptide-T-amide) in humans and to find out more about the ability of peptide T to prevent, halt, and/or reverse AIDS-associated immunologic disturbances.
- Trial name
- NCT00000393
- Testing
- Peptide T
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Mental Health (NIMH)
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
Background: PANS is an illness that comes on suddenly in children. The full name is Pediatric Acute-Onset Neuropsychiatric Syndrome. It can cause sudden obsessive-compulsive behaviors.
- Trial name
- NCT03507218
- Where
- 8 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Neurodevelopmental Disorders, Autism Spectrum Disorder
Patterns of Neurodevelopmental Disorders
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
- Conditions
- Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome
- Trial name
- NCT06213090
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Richard Frye
IBS - Irritable Bowel Syndrome, Ulcerative Colitis
The IMAGINE-SPOR CIHR Chronic Disease Network
The IMAGINE Cohort Study will identify and recruit a cohort of 8000 patients with IBS, IBD and healthy controls (2000 of each) who will be assessed in terms of their psychological status, dietary intake, gut microbiome…
- Conditions
- IBS - Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Healthy
- Trial name
- IMAGINE (NCT03131414)
- Testing
- Diet, Gastrointestinal microbiome
- Where
- Canada
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Long Covid19, Neuropsychiatric Symptoms
Electro-acupuncture for Long Covid Neuropsychiatric Symptoms
In this study, a 16-week randomized, sham-controlled, double-blinded clinical trial will be conducted to to investigate the efficacy and safety of electro-acupuncture compared to sham acupuncture for treatment of long covid…
- Conditions
- Long Covid19, Neuropsychiatric Symptoms, Electro-acupuncture
- Trial name
- NCT05890508
- Testing
- Acupuncture
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- Hong Kong Baptist University
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
Neuropsychiatric Syndromes
Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach
The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia…
- Trial name
- NCT03705715
- Testing
- PET with radiotracer [11C]PBR-28 ( or [11C]ER176), Affective challenge
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson Disease, Huntington Disease
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile…
- Conditions
- Parkinson Disease, Huntington Disease, Autistic Spectrum Disorders, Fragile X Syndrome
- Trial name
- FPEB (NCT00870974)
- Testing
- [18F]FPEB
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
Internet-based Coaching for Young Adults With Neuropsychiatric Disorders
Purpose: To develop a model for internet-based support and coaching to young adults with neuropsychiatric disorders (NPD). To improve the individual's psychosocial functioning and his/her understanding of how he/she is…
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Tourette's Disorder
- Trial name
- NCT02316145
- Testing
- Habilitation (Internet-based support and coaching)
- Volunteers
- 12 people
- Sponsor
- Vardalinstitutet The Swedish Institute for Health Sciences
Chronic Fatigue Syndrome
Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequelae of Post-SARS-CoV-2 Onset ME/CFS Versus Pre-Pandemic ME/CFS Patients
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex chronic illness impacting multiple body systems and characterized by activity-limiting fatigue and post exertional symptom exacerbation, affecting over 3.5…
- Trial name
- MECFS BBB (NCT07256795)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
ADA-SCID
Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
Background: Severe combined immunodeficiency (SCID) is a rare inherited disorder in which certain white blood cells have impaired function and are unable to properly fight infections.
- Trial name
- NCT01182857
- Sponsor
- National Human Genome Research Institute (NHGRI)
Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog")…
- Trial name
- PAISE-AriSE (NCT07714213)
- Testing
- Aripiprazole (low-dose, 1mg)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Christiana Franke
Stroke, Fatigue Symptom
Sleep-Disordered Breathing in the Acute Phase After Stroke and Neuropsychiatric Outcomes
In people who have had a stroke or a transient ischemic attack (TIA), it is common to have problems with breathing patterns during sleep, particularly a condition called obstructive sleep apnea.
- Conditions
- Stroke, Fatigue Symptom, Obstructive Sleep Apnea, Sleep Disordered Breathing (SDB)
- Trial name
- NCT06811948
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- Blekinge County Council Hospital
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study investigates the effectiveness of a medicinal cannabis extract (NTI164) with 0.08% THC in treating children with pediatric acute-onset neuropsychiatric syndrome (PANS) over a period of 18 to 54 weeks.
- Trial name
- CannaPANS (NCT06621888)
- Testing
- NTI164
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group